Why Oracle (ORCL) fell 2.88%

Oracle (ORCL) fell 2.88% on September 29, 2026 — Oncology AI in EHR workflow sparks concerns.

What happened

Oracle introduced oncology AI into its EHR (electronic health record) workflow, adding a new AI-native capability to its core enterprise software suite.

Why it moved

The market is discounting the move because oncology AI in EHR lacks visible customer wins or a clear path to material monetization; investors fear feature bloat without revenue lift, pulling back on Oracle's ability to…

Why it matters

Oracle is a crown jewel of enterprise software, but the Hyperscaler Capex cycle has shifted purchasing power toward cloud-native, AI-first platforms—Meta's concurrent enterprise push signals that traditional EHR vendors…

What would break the thesis

If Oracle announces signed deals or revenue-sharing models tied to the oncology AI rollout—especially from major health systems—the narrative flips to a credible new revenue stream, and the stock re-rates higher.

Sources

Trade ORCL 24/7 →

More ORCL moves